---
title: "Avalo Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286247433.md"
datetime: "2026-05-13T11:02:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286247433.md)
  - [en](https://longbridge.com/en/news/286247433.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286247433.md)
---

# Avalo Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.98.

EBIT: As of FY2026 Q1, the actual value is USD -21.7 M.

#### Cash and Investments

Cash, cash equivalents, and short-term investments totaled $82.0 million as of March 31, 2026, excluding subsequent financing . Cash and cash equivalents were $24,988 thousand as of March 31, 2026, an increase from $15,858 thousand as of December 31, 2025 . Short-term investments amounted to $57,005 thousand as of March 31, 2026, down from $82,478 thousand as of December 31, 2025 .

#### Operating Cash Flow

Net cash used in operating activities was - $17.7 million for the three months ended March 31, 2026 .

#### Operating Expenses

Research and development expenses were $14.0 million for the three months ended March 31, 2026, marking an increase of $4.9 million from the prior year . Specifically, research and development expenses were $14,047 thousand for the three months ended March 31, 2026, compared to $9,123 thousand for the same period in 2025 . General and administrative expenses reached $6.9 million for the three months ended March 31, 2026, an increase of $1.3 million from the prior year . General and administrative expenses were $6,854 thousand for the three months ended March 31, 2026, compared to $5,546 thousand for the three months ended March 31, 2025 . Total operating expenses for the three months ended March 31, 2026, were $20,901 thousand, up from $14,669 thousand for the corresponding period in 2025 .

#### Loss from Operations

Loss from operations was - $20,901 thousand for the three months ended March 31, 2026, compared to - $14,669 thousand for the three months ended March 31, 2025 .

#### Net Loss

Net loss was - $19.6 million for the three months ended March 31, 2026, compared to a net loss of - $13.1 million for the three months ended March 31, 2025 . This difference was primarily driven by a $6.2 million increase in operating expenses . The net loss was - $19,630 thousand for the three months ended March 31, 2026, compared to - $13,149 thousand for the three months ended March 31, 2025 .

#### Public Offering

Avalo Therapeutics, Inc. completed a public offering of equity securities, generating gross proceeds of $431.3 million . The underwritten public offering yielded net proceeds of approximately $405.0 million subsequent to March 31, 2026 .

#### Milestone Buyout Option

Avalo Therapeutics, Inc. paid $2.25 million for an option, exercisable within 90 days, to pay $5.125 million in cash or shares instead of a previously disclosed $15 million contingent milestone payment .

#### Balance Sheet Highlights

Total assets were $99,885 thousand as of March 31, 2026, a decrease from $116,458 thousand as of December 31, 2025 . Total liabilities were $31,565 thousand as of March 31, 2026, down from $33,409 thousand as of December 31, 2025 . Total stockholders’ equity was $68,320 thousand as of March 31, 2026, compared to $83,049 thousand as of December 31, 2025 .

#### Outlook / Guidance

Avalo Therapeutics, Inc. anticipates that its current cash, cash equivalents, and short-term investments will fund operations into 2029 . The company is positioned to advance abdakibart into a registrational phase 3 program following positive Phase 2 LOTUS trial results .

### Related Stocks

- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)

## Related News & Research

- [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)
- [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md)